Clinical trials: Intramuscular Injection
Melanoma, Ovarian Cancer
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
This is a Phase I, multi-center, multiple ascending dose study to evaluate the clinical safety and immune response of IDC-G305 when injected intramuscularly in patients with unresectable or metastatic cancer.
- Conditions
- Melanoma, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer
- Trial name
- NCT02015416
- Testing
- IDC-G305
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Peripheral Arterial Disease
SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease
To investigate the efficacy of the administration of JVS-100 delivered via direct intramuscular injections on a 3 month and 6 month composite endpoint of wound progression, healing and limb loss in patients with severe peripheral…
- Trial name
- STOP-PAD (NCT02544204)
- Testing
- JVS-100
- Where
- 24 sites in United States
- Volunteers
- 120 people
- Sponsor
- Juventas Therapeutics, Inc.
Prevention of Infectious Disease Caused by SARS-CoV-2
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA
This survey will be conducted for the subjects who participate in the priority survey (cohort survey) conducted by the Scientific Research Group of the Ministry of Health, Labour and Welfare at the initial stage of administration…
- Trial name
- NCT05135455
- Where
- 6 sites in Japan
- Volunteers
- 467 people
- Sponsor
- AstraZeneca
Opiod Use Disorder
Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)
This is an Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Naltrexone HCL to DLP-160 (Naltrexone implant) to Intramuscular Vivitrol®
- Trial name
- NCT05304364
- Testing
- Combination Product: Naltrexone
- Where
- Australia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Delpor, Inc.
Influenza
First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP
This study is a single center, randomized, double-blind, placebo-controlled, dose-finding, FIH, Phase 1 study to assess the safety, tolerability, and immunogenicity of the adjuvanted Universal Influenza Vaccine (fH1/DSP-0546LP)…
- Trial name
- NCT06460064
- Testing
- fH1 2 ug, fH1 8 ug, DSP-0546LP 2.5 ug
- Where
- Belgium
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma Co., Ltd.
Age-related Muscle Decline
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
This Phase 1/2a, open-label, non-randomized study is designed to evaluate the safety and tolerability of intramuscular AAV9-Follistatin gene therapy administered either as monotherapy or in combination with a VEGF-encoding…
- Trial name
- CALM-AF-AI (NCT07443826)
- Testing
- AAV9-Follistatin gene therapy, VEGF Plasmid
- Where
- Honduras
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Unlimited Biotechnology LLC
Anthrax
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
The purpose of this study is to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects.
- Trial name
- GC1109 (NCT01624532)
- Where
- South Korea
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program
The primary objective(s) of the study is to evaluate the impact of exposure to SC Peginterferon beta-1a or IM Interferon beta-1a before and during pregnancy on pregnancy outcome in female participants who had registered in the…
- Trial name
- NCT04655222
- Testing
- Interferon Beta Therapy
- Where
- Germany
- Volunteers
- 470 people
- Sponsor
- Biogen
Influenza Infection
Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants
The purpose of this study is to evaluate the safety and immunogenicity of an intramuscular injection of TAK-850 in healthy pediatric Japanese participants.
- Trial name
- NCT02367885
- Testing
- TAK-850 0.5 mL injection, TAK-850 0.25 mL injection
- Where
- 2 sites in Japan
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Takeda
Herpes Zoster
A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years
This is a randomized, observer blind and controlled study. Participants in low-dose and high-dose IM group will be randomized in a ratio of 2:1 to receive either the investigational product or the control.
- Trial name
- NCT05991427
- Testing
- Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV), Zoster Vaccine Recombinant, Adjuvanted (Shingrix), ChAdOx1-VZV
- Where
- Canada
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Needle-free Injector
Evaluation by Magnetic Resonance Imaging of Intramuscular Injections Performance in Thigh With 2 Configurations of the Needle-free Injector ZENEO®.
The aim of this study is to establish with measures of clinical parameters by Magnetic Resonance Imaging (MRI) (e.g. crossing of the muscle fascias, length of run, injection depth, volume injected) performance of 2 configurations…
- Trial name
- MRI (NCT05967013)
- Testing
- Injections in thigh of 0.625 mL of physiological serum with ZENEO® injector, on bare skin and through clothing.
- Where
- France
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Crossject
Schizophrenia
Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting formulation (in situ microparticle, ISM) of risperidone over four IM injections in the gluteal and deltoid muscle at 28-day intervals and…
- Trial name
- PRISMA-2 (NCT02086786)
- Testing
- Risperidone ISM
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Rabies, Japanese Encephalitis
Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers
This study evaluated the safety and immunogenicity of rabies vaccine and Japanese encephalitis vaccine in toddlers. All children developed adequate immune responses.
- Conditions
- Rabies, Japanese Encephalitis, Pre-Exposure Prophylaxis
- Trial name
- NCT00694460
- Testing
- Three 1 mL doses of Rabies vaccine and two JE vaccine, Three 0.5 mL doses of Rabies vaccine and two JE vaccine, Three 0.1mL doses of Rabies Vaccine and two JE vaccine
- Where
- Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novartis
Pneumococcal Infections
A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults
The purpose of this study is to evaluate the safety and immunogenicity of LBVE013 (Pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) or LBVE014 (Pneumococcal 14-valent conjugate vaccine [diphtheria CRM197…
- Trial name
- NCT02892812
- Testing
- Pneumococcal conjugate vaccine
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics properties of TNM002 following a single intramuscular dose in Chinese healthy adults.
- Trial name
- NCT05842798
- Testing
- TNM002
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
Opioid Overdose
Pharmacokinetic Evaluation of a New Naloxone Nasal Swab, Naloxone Nasal Spray, and Intramuscular Naloxone Injection in Healthy Volunteers
The study consists of two Phases with the first phase (Pilot Phase) divided into two sub phases. In each study phase, subjects will be admitted to the clinical unit from 10 hours prior to the first drug administration on Day -1…
- Trial name
- NCT05363501
- Testing
- IM Naloxone Injection, Naloxone Nasal Spray, Naloxone Nasal Swab
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pocket Naloxone Corp
Recurrent Vulvovaginal Candidiasis
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
Pevion Biotech develops a state-of-the-art vaccine against recurrent vulvovaginal candidiasis (RVVC) caused by the pathogenic form of Candida albicans especially in pre-menopausal women of childbearing age with a history of…
- Trial name
- NCT01067131
- Testing
- PEV7C1, PEV7C9, PEV7B2
- Where
- 2 sites in Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pevion Biotech Ltd
Healthy Volunteer, Fatigue
Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus
The goal of this study is to learn about the safety of Niagen®Plus, an injectable form of nicotinamide riboside (NR), and to see how it affects levels of NAD+ in the blood.
- Trial name
- NCT07251608
- Testing
- Niagen®Plus
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- ChromaDex, Inc.
Glabellar Lines
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05248880
- Testing
- AGN-151586
- Where
- 17 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- AbbVie
Diabetes, Diabetes Mellitus, Type 1
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of the trial is to compare pharmacokinetics (at which rate the body eliminates the substance from the body) of insulin aspart with fast-acting insulin human following intravenous (IV)…
- Trial name
- NCT01269606
- Testing
- insulin aspart, insulin human
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Novo Nordisk A/S